3rd Quarter - Report

W STRATEGIES, LLC for ALEXION PHARMACEUTICALS

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Education about the value of innovative new medicines and the Orphan Drug Act. H.R.1231/S.456: RACE for Children Act. H.R.2430/S.934: FDA Reauthorization Act of 2017. Education about the 340(b)m program. H.R.1628: American Health Care Act. Better Care Reconciliation Act and S. Better Care Reconciliation Act.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2430 (115th), H.R. 1628 (115th), S. 934 (115th), H.R. 1231 (115th), S. 456 (115th)

Medicare/Medicaid MMM

Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.